ACR-6840 / Acrivon Therap - LARVOL DELTA

Anticipated Upcoming Milestones (The Manila Times) - “Additional ACR-2316 Phase 1/2 clinical data for weekly and bi-weekly dosing regimens and transition into dose expansion in AP3-identified tumor types in 2026; Submit IND filing to the FDA for ACR-6840, or alternative CDK11 inhibitor candidate, in first half of 2027; Initiate additional internal programs utilizing the AP3 platform in 2026.”

IND • P1/2 data • Pipeline update • Solid Tumor

ACR-6840, a potential first-in-class CDK11 inhibitor, nominated as the next development candidate from company’s AP3-driven cell cycle program, with several promising back-up series also identified (Acrivon Press Release) - "IND submission anticipated in the fourth quarter of 2026."

IND • New molecule • Oncology